Oncternal Therapeutics (NASDAQ:ONCT) Stock Rating Reaffirmed by Brookline Capital Management

Oncternal Therapeutics (NASDAQ:ONCT)‘s stock had its “hold” rating reiterated by investment analysts at Brookline Capital Management in a research note issued on Thursday, Marketbeat Ratings reports.

A number of other analysts have also weighed in on ONCT. StockNews.com initiated coverage on shares of Oncternal Therapeutics in a report on Sunday, September 8th. They set a “hold” rating for the company. HC Wainwright dropped their price objective on Oncternal Therapeutics from $19.00 to $18.00 and set a “buy” rating for the company in a report on Monday, August 12th.

Oncternal Therapeutics Trading Down 14.1 %

Shares of NASDAQ:ONCT opened at $1.46 on Thursday. The stock has a market capitalization of $4.32 million, a P/E ratio of -0.12 and a beta of 1.39. The stock’s 50-day moving average price is $5.37 and its 200-day moving average price is $7.48. Oncternal Therapeutics has a 12-month low of $1.32 and a 12-month high of $13.14.

Oncternal Therapeutics (NASDAQ:ONCT) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($2.89) EPS for the quarter, topping analysts’ consensus estimates of ($3.03) by $0.14. The business had revenue of $0.80 million for the quarter, compared to analysts’ expectations of $0.24 million. Oncternal Therapeutics had a negative return on equity of 136.10% and a negative net margin of 1,948.70%. During the same period in the previous year, the firm earned ($3.00) EPS. As a group, research analysts predict that Oncternal Therapeutics will post -11.4 EPS for the current year.

Institutional Trading of Oncternal Therapeutics

A hedge fund recently bought a new stake in Oncternal Therapeutics stock. Pasadena Private Wealth LLC purchased a new position in Oncternal Therapeutics, Inc. (NASDAQ:ONCT) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 25,000 shares of the company’s stock, valued at approximately $190,000. Pasadena Private Wealth LLC owned about 0.84% of Oncternal Therapeutics as of its most recent SEC filing. 16.05% of the stock is currently owned by institutional investors and hedge funds.

About Oncternal Therapeutics

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.